|
gptkbp:instanceOf
|
gptkb:drug
beta blocker
|
|
gptkbp:ATCCode
|
gptkb:C07AB03
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:brand
|
gptkb:Tenormin
|
|
gptkbp:CASNumber
|
gptkb:29122-68-7
|
|
gptkbp:category
|
antianginal agent
antiarrhythmic agent
antihypertensive agent
|
|
gptkbp:chemicalFormula
|
C14H22N2O3
|
|
gptkbp:contraindication
|
asthma
heart block
severe bradycardia
|
|
gptkbp:discoveredBy
|
gptkb:ICI_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
6-7 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atenolol
|
|
gptkbp:interactsWith
|
gptkb:insulin
gptkb:clonidine
gptkb:digoxin
calcium channel blockers
|
|
gptkbp:introducedIn
|
1976
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
beta-1 adrenergic receptor antagonist
|
|
gptkbp:meltingPoint
|
152-155°C
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:molecularWeight
|
266.34 g/mol
|
|
gptkbp:overdoseSymptoms
|
heart failure
hypotension
bradycardia
|
|
gptkbp:patentExpired
|
true
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
6-16%
|
|
gptkbp:PubChem_CID
|
DB00335
2249
|
|
gptkbp:riskInPregnancy
|
may cause fetal harm
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
dizziness
fatigue
bradycardia
cold extremities
|
|
gptkbp:solubility
|
freely soluble
|
|
gptkbp:UNII
|
50VV3VW0TI
|
|
gptkbp:usedFor
|
gptkb:arrhythmia
myocardial infarction
hypertension
angina pectoris
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:ChEMBL1044
gptkb:CHEMBL123
gptkb:CHEMBL1428
gptkb:CHEMBL691
gptkb:CHEMBL1092
gptkb:CHEMBL1401
|
|
gptkbp:bfsLayer
|
6
|